Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention
The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.
The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.
Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.
Alterations conferring resistance to targeted agents were identified among 18% of samples from NSCLC, breast, colorectal, and prostate cancers, melanoma, and gastrointestinal stromal tumors.
Although these data did not demonstrate improved survival with the inclusion of a CT scan at routine follow-up visits, the authors noted that a longer follow-up time is necessary to identify any long-term OS benefits.
Researchers randomly assigned 713 patients with NSCLC who did not progress after 2 or more cycles of platinum-based concurrent chemoradiation therapy to receive durvalumab 10 mg/kg consolidation therapy or placebo for up to 12 months.
Researchers compared the efficacy of abemaciclib plus anastrozole or letrozole vs placebo plus anastrozole or letrozole among patients not previously treated with a systemic therapy.
The results of the study demonstrate that increased TIL levels may be associated with a greater response to pembrolizumab monotherapy in patients with mTNBC, especially in the first-line setting.
Patients who received osimertinib had a PFS of 18.9 months compared with 10.2 months among those who received SoC treatments (P < .0001).
Long-term hormone monotherapy has been the standard of care for patients with PCa for more than 60 years. The purpose of this study was to compare the efficacy of 2 new treatment standards using a patient subset of the STAMPEDE trial.
The phase 3 OAK trial demonstrated that previously treated patients with advanced NSCLC experienced prolonged OS with atezolizumab compared to docetaxel regardless of PD-L1 status.